TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology

MENLO PARK, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) — TeneoBio, Inc. yesterday presented preclinical data on its lead therapeutic candidate, TNB-383B, a multivalent anti-BCMAxCD3 at the American Society of Hematology annual meeting in Atlanta, Georgia.
Read more

Teneobio and Poseida Announce License Agreement for the Use of UniDab® in CAR T-Cell Therapy

MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) — Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of Teneobio’s UniDabs®, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy.
Read more

Teneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release

MENLO PARK, Calif., May 01, 2017 (GLOBE NEWSWIRE) — Teneobio, Inc, a next-generation antibody therapeutics company, announced today at the Protein Engineering Summit (PEGS) in Boston the discovery of a large panel of human anti-CD3 binders with diverse affinities and tune-able T-cell activation.
Read more